1. Home
  2. FSBC vs SNDX Comparison

FSBC vs SNDX Comparison

Compare FSBC & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Five Star Bancorp

FSBC

Five Star Bancorp

N/A

Current Price

$44.43

Market Cap

1.1B

Sector

Finance

ML Signal

N/A

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

N/A

Current Price

$9.83

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FSBC
SNDX
Founded
2002
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
FSBC
SNDX
Price
$44.43
$9.83
Analyst Decision
Buy
Strong Buy
Analyst Count
5
12
Target Price
★ $51.40
$35.45
AVG Volume (30 Days)
119.0K
★ 3.7M
Earning Date
10-26-2026
11-02-2026
Dividend Yield
★ 2.25%
N/A
EPS Growth
★ 28.32
11.56
EPS
★ 2.70
N/A
Revenue
N/A
★ $172,352,000.00
Revenue This Year
$25.54
$83.56
Revenue Next Year
$14.03
$45.01
P/E Ratio
$16.43
★ N/A
Revenue Growth
N/A
★ 627.84
52 Week Low
$32.20
$9.15
52 Week High
$50.26
$25.59

Technical Indicators

Market Signals
Indicator
FSBC
SNDX
Relative Strength Index (RSI) 50.50 27.45
Support Level $40.94 N/A
Resistance Level $47.23 $25.38
Average True Range (ATR) 1.28 1.03
MACD -0.04 -0.20
Stochastic Oscillator 27.43 8.93

Price Performance

Historical Comparison
FSBC
SNDX

About FSBC Five Star Bancorp

Five Star Bancorp is a bank holding company that operates in California through its subsidiary, a state-chartered non-member bank. The company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans, and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment: Banking.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: